Navigation Links
Novel link between excessive nutrient levels and insulin resistance
Date:2/21/2008

La Jolla, CA For quite some time now, scientists suspected the so-called hexosamine pathway a small side business of the main sugar processing enterprise inside a cell to be involved in the development of insulin resistance. But they could never quite put their finger on the underlying mechanism.

Now, researchers at the Salk Institute for Biological Studies have uncovered the long-missing molecular link: the enzyme OGT (short for O-linked -N-acetylglucosamine transferase), the last in a line of enzymes that shuttle sugars through the hexosamine pathway.

Their study revealed that OGT slams the brake on insulin signaling soon after insulin fires up the machinery that pulls glucose from the blood stream and squirrels it away inside liver or stashes the surplus energy in fat pads.

For the first time we have a real understanding of how the insulin signaling system is turned on and off, says Howard Hughes Medical Investigator Ronald M. Evans, Ph.D., a professor in the Salk Institutes Gene Expression Laboratory, who led the study that appears in the Feb. 21 issue of Nature.

He hopes that this could lead to a new class of insulin-sensitizing drugs that loosen the brake and let insulin work a little bit longer.

When insulin binds its receptor on the cell surface it sets off a cascade of intracellular signals resulting in the production of PIP3, a specialized lipid molecule that masterminds a whole army of molecules that work together to synthesize and store carbohydrates, lipids and proteins. But turning on a physiological process is only half the story, explains Evans. You also need instructions that tell the cell to get off the accelerator and put on the brake.

Postdoctoral researcher and first author Xiaoyong Yang, Ph.D., discovered that PIP3 oversees both. His experiments revealed that within minutes activation of the insulin signaling network coaxes OGT out of the nucleus and into the cytoplasm. It travels
'/>"/>

Contact: Gina Kirchweger
kirchweger@salk.edu
858-453-410-01340
Salk Institute
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Novel organic metal hybrids that will revolutionize materials science and chemical engineering
2. Novel mathematical model predicts new wave of drug-resistant HIV infections in San Francisco
3. Novel approach strips staph of virulence
4. UCSD research team identifies novel anticancer drug from the sea
5. Novel compound may lessen heart attack damage
6. Novel molecules developed at UB can boost vaccine potency
7. Novel small molecule therapy shows benefit for anemic patients via hydration of red blood cells
8. Novel vaccine concept developed by scientists at the Wistar Institute
9. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
10. Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology
11. Statement by AARP CEO Bill Novelli on President Bushs State of the Union
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 1Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 1Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 3Nostrils Compete to Relay Key Fragrance 54963 1Nostrils Compete to Relay Key Fragrance 54963 2